514 related articles for article (PubMed ID: 28515943)
21. A cost comparison of pembrolizumab: Fixed and weight-based dosing.
Slee AL; Coutsouvelis J; Tong B; Poole S; Zalcberg J
J Oncol Pharm Pract; 2024 May; ():10781552241255287. PubMed ID: 38780402
[TBL] [Abstract][Full Text] [Related]
22. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall E; Zhang J; Kim EJ; Hwang G; Chu G; Bhatia S; Reddy S
Cancer Med; 2020 Mar; 9(6):2106-2112. PubMed ID: 31994335
[TBL] [Abstract][Full Text] [Related]
23. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
[TBL] [Abstract][Full Text] [Related]
24. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
25. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Hamid O; Robert C; Ribas A; Hodi FS; Walpole E; Daud A; Arance AS; Brown E; Hoeller C; Mortier L; Schachter J; Long J; Ebbinghaus S; Ibrahim N; Butler M
Br J Cancer; 2018 Sep; 119(6):670-674. PubMed ID: 30202085
[TBL] [Abstract][Full Text] [Related]
26. A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059432
[TBL] [Abstract][Full Text] [Related]
27. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Bayle A; Besse B; Annereau M; Bonastre J
Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
[TBL] [Abstract][Full Text] [Related]
28. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
[TBL] [Abstract][Full Text] [Related]
29. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
30. Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
Heinhuis KM; Beijnen JH; Hendrikx JJMA
Int J Clin Pharm; 2020 Feb; 42(1):3-6. PubMed ID: 32026351
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
[TBL] [Abstract][Full Text] [Related]
34. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
35. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.
Bryant AK; Lewy JR; Bressler RD; Chopra Z; Gyori DJ; Bazzell BG; Moeller JA; Jacobson SI; Fendrick AM; Kerr EA; Ramnath N; Green MD; Hofer TP; Vaishnav P; Strohbehn GW
Lancet Oncol; 2024 Jun; 25(6):802-810. PubMed ID: 38821085
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
Proctor JR; Gartner EM; Gray TE; Davies RH
Cancer Chemother Pharmacol; 2022 Nov; 90(5):399-408. PubMed ID: 36102999
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
